Kjetil Elvevold has a PhD in liver physiology from the Institute of Medical Biology at the University of Tromsø. He worked on activation mechanisms of the innate immunsystem at Biotech Pharacon, he was a co-founder of biotech company D’Liver. D’Liver was a contract research organization that did pre-clinical research for the pharmaceutical industry. He has 3 peer-reviewed publications with Astra Zeneca. Since 2015, he has been conducting research on lipid nanoparticles with mRNA (the same technology used in vaccines from Moderna and Pfizer). Today he is engaged in a project where the goal is to deliver lipid nanoparticles with siRNA (silencing RNA) to specific liver cells in research animals.